Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2‐negative, Hormone Receptor‐positive Early Breast Cancer

[1]  Tanja Fehm,et al.  Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer , 2016, Clinical Cancer Research.

[2]  V. Valero,et al.  Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. , 2015, JAMA oncology.

[3]  Tanja Fehm,et al.  Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients , 2014, Journal of the National Cancer Institute.

[4]  M. Rezai,et al.  Evaluation of Two Different Analytical Methods for Circulating Tumor Cell Detection in Peripheral Blood of Patients with Primary Breast Cancer , 2014, BioMed research international.

[5]  I. Vermes,et al.  Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer , 2012, Breast Cancer Research.

[6]  H. Kuerer,et al.  Circulating tumour cells in non-metastatic breast cancer: a prospective study. , 2012, The Lancet. Oncology.

[7]  K. Pantel,et al.  Clinical relevance and biology of circulating tumor cells , 2011, Breast Cancer Research.

[8]  M. Beckmann,et al.  The German SUCCESS C Study – The First European Lifestyle Study on Breast Cancer , 2010, Breast Care.

[9]  V. Cornelius,et al.  Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials , 2010, BMC Cancer.

[10]  J. Dixon,et al.  Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Funda Meric-Bernstam,et al.  HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer , 2009, Breast Cancer Research and Treatment.

[12]  Anne Vincent-Salomon,et al.  Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial , 2008, Clinical Cancer Research.

[13]  R. Venkatraman.  HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials , 2008 .

[14]  F. Holmes,et al.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[16]  D. Tu,et al.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Fehm,et al.  Circulating tumor cells in breast cancer--current status and perspectives. , 2016, Critical reviews in oncology/hematology.

[18]  Leon W M M Terstappen,et al.  Circulating tumor cells before and during follow-up after breast cancer surgery. , 2015, International journal of oncology.

[19]  M. Espié,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.